New Sjögren's drug shows promise in small study

NCT ID NCT05124925

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a drug called ianalumab in 21 adults with Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth. The goal was to understand how the drug works in the salivary glands and check its safety. Participants received injections of ianalumab and had biopsies to measure changes in immune cells. The results will help researchers decide whether to test the drug in larger trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ianalumab (a biologic drug given as an injection)
What this could lead to: If successful, this study could help explain how ianalumab works in Sjögren's syndrome and support development of a new treatment option for patients.
What could go wrong: This is a small, early-phase study with only 21 participants and no placebo group. Results may not apply to all patients, and the drug may cause side effects or fail to show clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SJOGREN SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome Sjogren syndrome Xerostomia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SJOGREN SYNDROME

Contacts and locations

Locations

Novartis Investigative Site

Brest, 29200, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.